vs
Side-by-side financial comparison of Primerica, Inc. (PRI) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Primerica, Inc. is the larger business by last-quarter revenue ($872.7M vs $619.8M, roughly 1.4× QuidelOrtho Corp). Primerica, Inc. runs the higher net margin — 21.8% vs -14.8%, a 36.6% gap on every dollar of revenue. On growth, Primerica, Inc. posted the faster year-over-year revenue change (8.4% vs -10.5%). Over the past eight quarters, Primerica, Inc.'s revenue compounded faster (4.2% CAGR vs -6.6%).
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
PRI vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $872.7M | $619.8M |
| Net Profit | $190.1M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 21.8% | -14.8% |
| Revenue YoY | 8.4% | -10.5% |
| Net Profit YoY | 12.4% | — |
| EPS (diluted) | $5.97 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $872.7M | $619.8M | ||
| Q4 25 | $853.7M | — | ||
| Q3 25 | $839.9M | $699.9M | ||
| Q2 25 | $793.3M | $613.9M | ||
| Q1 25 | $804.8M | $692.8M | ||
| Q4 24 | $768.8M | $707.8M | ||
| Q3 24 | $774.1M | $727.1M | ||
| Q2 24 | $803.4M | $637.0M |
| Q1 26 | $190.1M | $-91.8M | ||
| Q4 25 | $197.0M | — | ||
| Q3 25 | $206.8M | $-733.0M | ||
| Q2 25 | $178.3M | $-255.4M | ||
| Q1 25 | $169.1M | $-12.7M | ||
| Q4 24 | $167.1M | $-178.4M | ||
| Q3 24 | $164.4M | $-19.9M | ||
| Q2 24 | $1.2M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 98.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 28.9% | — | ||
| Q3 25 | 32.3% | -100.7% | ||
| Q2 25 | 29.6% | -29.4% | ||
| Q1 25 | 27.5% | 4.7% | ||
| Q4 24 | 64.7% | -14.2% | ||
| Q3 24 | 32.9% | 2.1% | ||
| Q2 24 | 1.0% | -18.4% |
| Q1 26 | 21.8% | -14.8% | ||
| Q4 25 | 23.1% | — | ||
| Q3 25 | 24.6% | -104.7% | ||
| Q2 25 | 22.5% | -41.6% | ||
| Q1 25 | 21.0% | -1.8% | ||
| Q4 24 | 21.7% | -25.2% | ||
| Q3 24 | 21.2% | -2.7% | ||
| Q2 24 | 0.1% | -23.2% |
| Q1 26 | $5.97 | $-1.35 | ||
| Q4 25 | $6.11 | — | ||
| Q3 25 | $6.35 | $-10.78 | ||
| Q2 25 | $5.40 | $-3.77 | ||
| Q1 25 | $5.05 | $-0.19 | ||
| Q4 24 | $4.92 | $-2.54 | ||
| Q3 24 | $4.83 | $-0.30 | ||
| Q2 24 | $0.03 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $645.8M | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $2.5B | $1.9B |
| Total Assets | $14.7B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $645.8M | $140.4M | ||
| Q4 25 | $756.2M | — | ||
| Q3 25 | $644.9M | $98.1M | ||
| Q2 25 | $621.2M | $151.7M | ||
| Q1 25 | $625.1M | $127.1M | ||
| Q4 24 | $687.8M | $98.3M | ||
| Q3 24 | $550.1M | $143.7M | ||
| Q2 24 | $627.3M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | $2.5B | $1.9B | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.3B | $2.0B | ||
| Q2 25 | $2.3B | $2.8B | ||
| Q1 25 | $2.3B | $3.0B | ||
| Q4 24 | $2.3B | $3.0B | ||
| Q3 24 | $1.9B | $3.2B | ||
| Q2 24 | $2.1B | $3.2B |
| Q1 26 | $14.7B | $5.6B | ||
| Q4 25 | $15.0B | — | ||
| Q3 25 | $14.8B | $5.7B | ||
| Q2 25 | $14.8B | $6.4B | ||
| Q1 25 | $14.6B | $6.5B | ||
| Q4 24 | $14.6B | $6.4B | ||
| Q3 24 | $14.8B | $6.8B | ||
| Q2 24 | $14.6B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRI
Segment breakdown not available.
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
